Pfizer Inc (NYSE PFE) stock is up 1.7% at $27.04 at last check, following news a late-stage trial of its respiratory syncytial virus (RSV) vaccine Abrysvo generated an immune response in higher risk adults under the age of 60. The company plans to seek expanded approval of the vaccine for ages 18 to 59.
Shares are still struggling with resistance at the $29 level, which has been in place since January and rejected a mid-March rally off 11-year lows. In the last 12 months, PFE shed 35.3%.
Short-term options traders lean bearish. This is per PFE's Schaeffer's put/call open interest ratio (SOIR) of 1.05 that sits at the top percentile of annual readings. This means a shift in sentiment could generate tailwinds for Pfizer stock.
There's also room for optimism in the options pits. In fact, 11 of the 20 brokerage firms in question still rate the security a tepid "hold," while the remaining nine say "buy" or better.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
